Company intelligence

AGEN

Agenus Inc. · NASDAQ · Healthcare

Price$8.10-3.10% · −$0.26

Market cap337.33MEquity value

P / E3.2Trailing ratio

Volume335.33KLatest session

Market data

AGEN price chart

TradingView

Related signals

1 min delayed

Browse public AGEN signals with their source context and measured market impact. Open any signal for its permanent analysis page.

AGENJul 13, 2026-32.72% since signal

Agenus pivots to ROBBIN, secures capital to extend runway to 2031

Agenus outlined a strategic pivot accompanying a private placement that backs the ROBBIN Phase 3 program while shelving BATTMAN. The $85 million upfront and up to $255 million in warrants extend cash runway to 2031, signaling management’s conviction in ROBBIN and investor validation from notable backers. The market rewarded the plan with a sharp rally, underscoring the perceived shift in pipeline value.

View signal analysis

AGENJun 4, 2025-12.91% since signal

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Zydus Lifesciences to acquire Agenus' biologics manufacturing facilities for $75 million. Agenus will streamline focus on colorectal cancer drug development post-acquisition. Analysts predict bot/BAL approval by 2028-2029, with significant market potential. Agenus aims to reduce cash burn below $50 million in 2025; cash balance at $18.5 million. Agenus stock rose 17% to $5.86 following recent developments.

View signal analysis

Research